Economic Appraisal of the Boston Ocular Surface Prosthesis

References 

1. Javitt JC, Zhou Z, Willke RJ. Association between vision loss and higher medical care costs in Medicare beneficiaries. Ophthalmology. 2007;114:238–245
   • Abstract
   • Full Text
   • Full-Text PDF (303 KB)
   • CrossRef
2. US National Eye Institute. Facts about the cornea and corneal diseases (Keratoconus). Updated Nov 2008 www.nei.nih.gov/health/cornealdisease/index.asp#hAccessed: November 10, 2008
3. Jacobs DS, Rosenthal P. Boston scleral lens prosthetic device for treatment of ocular surface disease in chronic graft-versus-host disease. Cornea. 2007;26:1195–1199
   • CrossRef
4. Romero-Rangel T, Stavrou P, Cotter J, Rosenthal P, Baltatzis S, Foster CS. Gas-permeable scleral contact lens therapy in ocular surface disease. Am J Ophthalmol. 2000;130:25–32
   • Abstract
   • Full Text
   • Full-Text PDF (582 KB)
   • CrossRef
5. Rosenthal P, Cotter JM, Baum J. Treatment of persistent corneal epithelial defect with extended wear of a fluid-ventilated gas-permeable scleral contact lens. Am J Ophthalmol. 2000;130:33–41
   • Abstract
   • Full Text
   • Full-Text PDF (525 KB)
   • CrossRef
6. Rosenthal P, Croteau A. Fluid-ventilated, gas-permeable scleral contact lens is an effective option for managing severe ocular surface disease and many corneal disorders that would otherwise require penetrating keratoplasty. Eye Contact Lens. 2005;31:130–134
   • MEDLINE
   • CrossRef
7. Takahide K, Parker PM, Wu M, et al. Use of fluid-ventilated, gas-permeable scleral lens for management of severe keratoconjunctivitis sicca secondary to chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2007;13:1016–1021
   • Abstract
   • Full Text
   • Full-Text PDF (1430 KB)
   • CrossRef
8. Stason WB, Razavi M, Jacobs DS, et al. Clinical benefits of the Boston ocular surface prosthesis. Am J Opthalmol. Forthcoming.
9. Mangione CM, Lee PP, Gutierrez PR, Spritzer K, Berry S, Hays RD. Development of the 25-item National Eye Institute Visual Function Questionnaire (VFQ-25). Arch Ophthalmol. 2001;119:1050–1058
   • MEDLINE
10. US Securities and Exchange Commission. Bausch & Lomb Incorporated's 2006 Form 10-K. 2007;http://www.sec.gov/Archives/edgar/data/10427/000001042707000105/bol10k2006.htmAccessed: June 25, 2009
11. DeNavas-Walt C, Proctor BD, Smith JC. Income, poverty, and health insurance coverage in the United States: 2007 (Current population reports (P60-235)). 2007;http://www.census.gov/prod/2008pubs/p60-235.pdfAccessed: July 7, 2009
12. IRS Standard Mileage Rates (2006 mileage rates). About.com. Tax planning: US http://taxes.about.com/od/2006taxes/qt/IRSMileageRate.htmAccessed: May 1, 2009
13. US General Services Administration. Domestic per diem rates, 2006, Massachusetts. http://www.gsa.gov/Portal/gsa/ep/contentView.do?queryYear=2006&contentType=GSA_BASIC&contentId=17943&queryState=Massachusetts&noc=TAccessed: May 1, 2009
14. Massof RW, Ahmadian L. What do different visual function questionnaires measure?. Ophthalmic Epidemiol. 2007;14:198–204
    • CrossRef
15. Brown GC. Vision and quality-of-life. Trans Am Ophthalmol Soc. 1999;97:473–511
    • MEDLINE
16. Gold M, Siegel J, Russell L, Weinstein M. Cost-effectiveness analysis in health and medicine. New York, New York: Oxford University Press; 1966;
17. Steinberg EP, Tielsch JM, Schein OD, et al. The VF-14 (An index of functional impairment in patients with cataract). Arch Ophthalmol. 1994;112:630–638
    • MEDLINE
18. Boisjoly H, Gresset J, Charest M, et al. The VF-14 index of visual function in recipients of a corneal graft: a 2-year follow-up study. Am J Ophthalmol. 2002;134:166–171
    • Abstract
    • Full Text
    • Full-Text PDF (105 KB)
    • CrossRef
19. Jacobson G, Frick K, Massof R. Impact of low vision and chronic ophthalmic conditions on absenteeism and lost work productivity 2005; 22: abstract no. 4117. http://gateway.nlm.nih.gov/MeetingAbstracts/ma?f=103623580.htmlAccessed: July 6, 2009
20. US Food and Drug Administration. Federal Register Vol. 64 No. 221 (Food labeling: Trans fatty acids in nutrition labeling, nutrient content claims, and health claims; proposed rule). In: November 1999;p. 62;772 http://vm.cfsan.fda.gov/∼lrd/fr991117.htmlAccessed: March 5, 2009
21. Cutler DM, Richardson E. Measuring the health of the U.S. population. 1997;http://ideas.repec.org/a/bin/bpeajo/v28y1997i1997-1p217-282.htmlAccessed: March 5, 2009
22. Cohen J. Statistical power analysis for the behavioral sciences. 2nd ed.. Hillsdale, New Jersey: Lawrence Erlbaum Associates; 1988;
23. Webster BH, Bishaw A. Income, earnings, and poverty data from the 2006 American Community Survey (ACS-08). 2007;http://www.census.gov/prod/2007pubs/acs-08.pdfAccessed: March 5, 2009
24. Zarkin GA, Dean N, Mauskopf A, Williams R. Potential health benefits of nutrition label changes. Am J Public Health. 1993;83:717–724
    • MEDLINE
    • CrossRef
25. Roe RH, Lass JH, Brown GC, Brown MM. The value-based medicine comparative effectiveness and cost-effectiveness of penetrating keratoplasty for keratoconus. Cornea. 2008;27:1001–1007
    • CrossRef
26. Pramanik S, Musch DC, Sutphin JE, Farjo AA. Extended long-term outcomes of penetrating keratoplasty for keratoconus. Ophthalmology. 2006;113:1633–1638
    • Abstract
    • Full Text
    • Full-Text PDF (265 KB)
    • CrossRef